Kiniksa Pharmaceuticals Interna (KNSA) Stock Price & How to Invest

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Its franchise is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis (a painful inflammatory condition of the heart lining) that it commercializes in the US under a collaboration with Regeneron. ARCALYST drove roughly $677.5 million of net product revenue in 2025, up about 62% from 2024, and the company reported roughly $214.3 million in Q1 2026 (up about 56% year over year), leading management to raise full-year 2026 ARCALYST guidance to roughly $930 to $945 million.

The investment picture is unusual for a biotech of this size: Kiniksa is already profitable, reporting positive net income and diluted EPS, while still growing revenue in the mid-to-high double digits. The bull framing is expanding prescriber adoption and a shift toward chronic disease management in recurrent pericarditis, plus an internal IL-1R pipeline (KPL-387 and KPL-1161) meant to extend the franchise beyond ARCALYST. The bear framing is concentration risk: nearly all revenue comes from one product in one indication, and the eventual loss of exclusivity plus competitive or pipeline setbacks would hit hard given the elevated valuation (a trailing P/E well above the broader market).

The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. The stock also trades at a high trailing earnings multiple, so a growth deceleration or a guidance miss could compress the valuation sharply. The pipeline (KPL-387, KPL-1161) is early and binary: clinical failures would remove the main franchise-extension thesis. ARCALYST is co-developed with Regeneron, so collaboration economics and terms matter to Kiniksa's share of profits. As a small-cap biotech, the shares are volatile and sensitive to single data readouts.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Kiniksa Pharmaceuticals Interna's investor relations page or your broker.

• Revenue (TTM): ~$754M
• Net income (TTM): ~$73M
• Market cap: ~$5.2B
• P/E (trailing): ~74x
• Cash: ~$468M
• 2026 ARCALYST guidance: ~$930-945M

As of July 2026, Kiniksa carried a market cap of roughly $5.2 billion against trailing revenue near $754 million and net income around $73 million, for a trailing P/E in the mid-70s. That multiple reflects both rare biotech profitability and expectations that ARCALYST keeps compounding toward the raised 2026 guidance of roughly $930 to $945 million.

There are three common ways to get KNSA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so KNSA sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where KNSA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Kiniksa is a rare profitable small-cap biotech compounding ARCALYST sales, with the pipeline and patent cliff around ARCALYST as the two swing factors.

Whether KNSA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KNSA a buy?, and where the stock could go from here in the KNSA stock forecast.

For income investors, whether KNSA pays a dividend and how the payout looks is covered in does KNSA pay a dividend?